Rapid absorption of nicotine from new nicotine gum formulations

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 3, 2009, Pages 380-384

  Shiffman, Saul ^a   Cone, Edward J ^a,b   Buchhalter, August R ^a   Henningfield, Jack E ^a,b   Rohay, Jeffrey M ^a   Gitchell, Joe G ^a   Pinney, John M ^a   Chau, Tommy ^c  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Nutravail Technologies   (United States)

Author keywords

Cigarette smoking; Craving relief; Gum; Nicotine; Nicotine replacement; Pharmacokinetics; Smoking cessation

Indexed keywords

NICOTINE GUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARESTHESIA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHEWING GUM; CHROMATOGRAPHY, GAS; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; YOUNG ADULT;

EID: 57449095857     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.08.012     Document Type: Article

References (35)

1. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36 (1996) 597-613
2. Benowitz N.L., Swan G.E., Jacob III P., Lessov-Schlaggar C.N., and Tyndale R.F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80 (2006) 457-467
3. Bliss R.E., Garvey A.J., Heinold J.W., and Hitchcock J.L. The influence of situation and coping on relapse crisis outcomes after smoking cessation. J Consult Clin Psychol 57 (1989) 443-449
4. Centers for Disease Control and Prevention. Use of FDA-approved pharmacologic treatments for tobacco dependence - United States, 1984-1998. Morb Mort Wkly Rep 49 (2000) 665-668
5. Chau TL, Pinney JM, Henningfield JE, Cone EJ, Shiffman SM, Gitchell JG. Medicinal delivery system, and related methods. 2008/0020050. 2008. Ref Type: Patent
6. Cherukuri SR, Pinney JM, Henningfield JE, Sasan A, Cone EJ, Shiffman S, et al. Medicated chewing gum delivery system for nicotine. JSR, LLC. [US 6,344,222]. 2002. Ref Type: Patent.
7. Choi J.H., Dresler C.M., Norton M.R., and Strahs K.R. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5 (2003) 635-644
8. Feyerabend C., and Russell M.A. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol 42 (1990) 450-452
9. Fiore M.C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 45 (2000) 1196-1199
10. Fiore M.C., Jaen C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. U.S. Department of Health and Human Services (2008), Public Health Service, Rockville, MD
11. Foulds J., Ramstrom L., Burke M., and Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 12 (2003) 349-359
12. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
13. Henningfield J.E. Nicotine medications for smoking cessation. N Engl J Med 333 (1995) 1196-1203
14. Henningfield J.E., and Keenan R.M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61 (1993) 743-750
15. Henningfield J.E., and Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J 53 suppl (1998) 75-114
16. Henningfield J.E., Radzius A., Cooper T.M., and Clayton R.R. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA 264 (1990) 1560-1564
17. Henningfield J.E., Fant R.V., Buchhalter A.R., and Stitzer M.L. Pharmacotherapy for nicotine dependence. CA: Cancer J Clin 55 (2005) 281-299
18. Lunell E., Molander L., and Andersson M. Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant. Eur J Clin Pharmacol 48 (1995) 71-75
19. Molander L., and Lunell E. Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 56 (2001) 813-819
20. Niaura R.S., Rohsenow D.J., Binkoff J.A., Monti P.M., Pedraza M., and Abrams D.B. Relevance of cue reactivity to understanding alcohol and smoking relapse. J Abnorm Psychology 97 (1988) 133-152
21. Niaura R., Sayette M., Shiffman S., Glover E.D., Nides M., Shelanski M., et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction 100 (2005) 1720-1730
22. Pinney JM, Henningfield JE, Shiffman S, Gitchell JG, Cone EJ. Two-stage transmucosal medicine delivery system for symptom relief. JSR, LLC. [US 6,358,060]. 2002. Ref Type: Patent.
23. Pinney JM, Henningfield JE, Shiffman S, Gitchell J, Cone EJ. Two-stage transmucosal medicine delivery system for symptom relief. JSR, LLC. [US 6,893,654]. 2005. Ref Type: Patent.
24. Rose J.E. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 184 (2006) 274-285
25. Rowland M., and Tozer T.N. Clinical pharmacokinetics: concepts and applications (1989), Lea & Febiger, Philadelphia
26. Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can't quit (2007), RCP, London Ref Type: Report
27. Sachs D.P. Tobacco dependence: pathophysiology & treatment. In: Hodgkin J.E., Connors G.L., and Celli B.R. (Eds). Pulmonary rehabilitation: guidelines for success. 4th ed. (2000), Lippincott Williams & Wilkins, Inc.
28. Schneider N.G., Olmstead R.E., Franzon M.A., and Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 40 (2001) 661-684
29. Schuh K.J., Schuh L.M., Henningfield J.E., and Stitzer M.L. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 130 (1997) 352-361
30. Shiffman S., Paty J.A., Gnys M., Kassel J.A., and Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64 (1996) 366-379
31. Shiffman S., Dresler C.M., Hajek P., Gilburt S.J., Targett D.A., and Strahs K.R. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162 (2002) 1267-1276
32. Shiffman S., Shadel W.G., Niaura R., Khayrallah M.A., Jorenby D.E., Ryan C.F., et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl) 166 (2003) 343-350
33. Stead L.F., Perera R., Bullen C., Mant D., and Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2008) CD000146
34. Stitzer M.L., and De Wit H. Abuse liability of nicotine. In: Benowitz N.L. (Ed). Nicotine safety and toxicity (1998), Oxford University Press, New York 119-131
35. Sumner W. Permissive nicotine regulation as a complement to traditional tobacco control. BMC Public Health 5 (2005) 18